Dynavax Technologies Corporation (NASDAQ:DVAX) Receives $24.33 Average Price Target from Analysts

Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) have been assigned an average rating of “Hold” from the five ratings firms that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating and three have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $24.3333.

A number of equities research analysts have weighed in on DVAX shares. Weiss Ratings reissued a “sell (d)” rating on shares of Dynavax Technologies in a report on Wednesday, October 8th. JMP Securities reissued a “market outperform” rating and set a $32.00 price objective on shares of Dynavax Technologies in a research report on Friday, August 22nd. Finally, Wall Street Zen upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Saturday, August 9th.

Dynavax Technologies Stock Performance

DVAX stock opened at $11.44 on Friday. The stock’s fifty day moving average is $10.31 and its two-hundred day moving average is $10.30. Dynavax Technologies has a 1 year low of $9.20 and a 1 year high of $14.63. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -24.87 and a beta of 1.09. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.01 and a current ratio of 6.65.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.07. The business had revenue of $94.88 million during the quarter, compared to the consensus estimate of $94.00 million. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%. On average, research analysts predict that Dynavax Technologies will post 0.32 EPS for the current year.

Institutional Investors Weigh In On Dynavax Technologies

A number of institutional investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd raised its stake in Dynavax Technologies by 5,485.7% during the first quarter. Caitong International Asset Management Co. Ltd now owns 2,346 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 2,304 shares in the last quarter. Hantz Financial Services Inc. lifted its holdings in Dynavax Technologies by 236.9% during the third quarter. Hantz Financial Services Inc. now owns 3,854 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 2,710 shares in the last quarter. LSV Asset Management bought a new stake in shares of Dynavax Technologies in the third quarter valued at about $89,000. Osaic Holdings Inc. grew its holdings in shares of Dynavax Technologies by 15.1% in the 2nd quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 1,226 shares in the last quarter. Finally, Callan Family Office LLC bought a new position in shares of Dynavax Technologies in the 2nd quarter valued at about $107,000. 96.96% of the stock is owned by institutional investors and hedge funds.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.